Back to top

Novo Nordisk Enters Oversold Territory
June 25, 2013

Read MoreHide Full Article

Novo Nordisk ’s (NVO - Free Report) share price has entered into oversold territory with an RSI value of 23.85. The Zacks Consensus Estimate on Novo Nordisk’s earnings for the full year period have moved higher by 16 cents over the past two months to $8.27 per share. Currently, Novo Nordisk is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (NVO - Free Report) after its recent drop.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Novo Nordisk A/S (NVO) - free report >>


More from Zacks Tale of the Tape

You May Like